Stable growth and transition to a renewed growth phase through a better-balanced business portfolio
First written in FY2016. 16 of 32 entries say "Softened", first in FY2020-Q1. Latest entry: 2026-08-20.
Intertrade moved to the "Worse" side of this theme in 2020, 6 years before the typical company in this theme (2026).
The whole theme swung hardest in 2024: 3 of 22 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- FY2026-H1SoftenedAnnual report
「Financial solutions business 694 79.9 Business solutions business 118 13.7 Healthcare business 55 6.4」
Year on year, the financial solutions business's share rose from 79.0% to 79.9%, while the business solutions business declined from 14.6% to 13.7% and the healthcare business was flat at 6.4%. Portfolio diversification weakened modestly. - FY2025SoftenedAnnual report
「Financial solutions business 1,473 80.2 Business solutions business 258 14.1 Healthcare business 104 5.7」
The financial solutions business's share rose from 78.1% in the previous fiscal year to 80.2%, while the business solutions business declined from 16.2% to 14.1%. The healthcare business was flat at 5.7%, weakening portfolio diversification. - FY2025-H1AdvancedAnnual report
「Financial solutions business 682 79.0 Business solutions business 125 14.6 Healthcare business 55 6.4」
Year on year, the financial solutions business's share declined from 79.9% to 79.0%, while the business solutions and healthcare businesses rose from 13.9% to 14.6% and from 6.2% to 6.4%, respectively. Concentration in the financial business eased modestly and mix-based diversification advanced. - FY2024Changes in the mix between the financial and business solutions businesses and contraction in healthcareAnnual report
「The Group will secure stable orders in each of the financial solutions, business solutions and healthcare businesses and transition to a renewed growth phase.」
For the full year, the revenue mix was 78.1% for the financial solutions business, 16.2% for the business solutions business and 5.7% for the healthcare business. The financial business's share declined and the business solutions business's share rose, while healthcare declined from 7.2% to 5.7%. - FY2024-Q2SoftenedAnnual report
「Financial solutions business 750 79.9 Business solutions business 131 13.9 Healthcare business 58 6.2」
Year on year, the financial solutions business's share rose from 78.9% to 79.9% and the business solutions business from 13.0% to 13.9%, while the healthcare business declined from 8.1% to 6.2%. The contraction in the healthcare business weakened portfolio diversification. - FY2024-Q1SoftenedAnnual report
「Financial solutions business 411 82.6 Business solutions business 55 11.1 Healthcare business 31 6.3」
Compared with the same period of the previous year, the financial solutions business's revenue mix rose from 79.9% to 82.6%, while the business solutions business declined from 11.9% to 11.1% and the healthcare business from 8.2% to 6.3%. Business portfolio diversification is weakening. - FY2023RestatedAnnual report
「The Group will secure stable orders in each of the financial solutions, business solutions and healthcare businesses and transition to a renewed growth phase.」
The Group continues to pursue a policy of securing stable orders in each of the 3 businesses and transitioning to a renewed growth phase. The revenue mix was 80.0% for financial, 12.8% for business solutions and 7.2% for healthcare. - FY2023-Q3AdvancedAnnual report
「Financial solutions business 1,136 80.5 Business solutions business 171 12.2 Healthcare business 103 7.3」
The financial solutions business's revenue mix declined from 81.6% in the same period of the previous year to 80.5%, while the business solutions business rose from 11.1% to 12.2%. The healthcare business remained at 7.3%, and concentration in the financial business eased modestly. - FY2023-Q2AdvancedAnnual report
「Financial solutions business 735 78.9 Business solutions business 120 13.0 Healthcare business 75 8.1」
The financial solutions business's revenue mix declined from 81.3% in the same period of the previous year to 78.9%, while the business solutions and healthcare businesses rose from 11.4% to 13.0% and from 7.3% to 8.1%, respectively. Business portfolio diversification advanced from the same period of the previous year. - FY2023-Q1AdvancedAnnual report
「Financial solutions business 368 79.9 Business solutions business 54 11.9 Healthcare business 38 8.2」
The financial solutions business's revenue mix declined from 81.2% in the same period of the previous year to 79.9%, while the business solutions business rose from 9.9% to 11.9%. The healthcare business declined from 8.9% to 8.2%, but concentration in the financial business eased modestly from the same period of the previous year. - FY2022AdvancedAnnual report
「Financial solutions business 1,646 80.1 Business solutions business 277 13.5 Healthcare business 132 6.4」
The financial solutions business's share declined from 81.5% in the previous fiscal year to 80.1%, while the business solutions and healthcare businesses rose from 12.4% and 6.1% to 13.5% and 6.4%, respectively. Diversification advanced modestly, but concentration in the financial business remains high. - FY2022-Q3SoftenedAnnual report
「Financial solutions business 1,173 81.6 Business solutions business 159 11.1 Healthcare business 105 7.3」
The financial solutions business's revenue mix rose to 81.6%, while the business solutions business declined to 11.1%. The healthcare business rose to 7.3%, but concentration in the financial solutions business continued overall and progress in portfolio diversification remained limited. - FY2022-Q2SoftenedAnnual report
「Financial solutions business 757 81.3 Business solutions business 105 11.4 Healthcare business 68 7.3」
The financial solutions business's revenue mix rose from 79.0% in the same period of the previous year to 81.3%, while the business solutions business declined from 13.6% to 11.4%. The healthcare business also declined from 7.4% to 7.3%, weakening business portfolio diversification. - FY2022-Q1SoftenedAnnual report
「Financial solutions business 335 81.2 Business solutions business 40 9.9 Healthcare business 36 8.9」
The financial solutions business's share rose from 75.3% in the same period of the previous year to 81.2%, while the business solutions business declined from 17.4% to 9.9%. The healthcare business rose from 7.3% to 8.9%, but overall concentration in the financial solutions business increased and portfolio diversification weakened. - FY2021SoftenedAnnual report
「Financial solutions business 1,759 81.5 Business solutions business 267 12.4 Healthcare business 130 6.1」
The financial solutions business's revenue mix rose to 81.5%, while the business solutions and healthcare businesses accounted for 12.4% and 6.1%, respectively. Portfolio improvement through diversification across the 3 businesses is weakening. - FY2021-Q3SoftenedAnnual report
「Financial solutions business 1,275 81.5 Business solutions business 190 12.2 Healthcare business 99 6.3」
While the financial solutions business's revenue mix rose to 81.5%, the business solutions and healthcare businesses accounted for 12.2% and 6.3%, respectively, further weakening portfolio diversification. - FY2021-Q2SoftenedAnnual report
「Financial solutions business 778 79.0 Business solutions business 134 13.6 Healthcare business 72 7.4」
The financial solutions business's revenue mix rose from 75.3% in the previous quarter to 79.0%, while the business solutions business declined from 17.4% to 13.6%. The healthcare business was 7.4%, compared with 7.3%, increasing the overall concentration in the financial business. - FY2021-Q1SoftenedAnnual report
「Financial solutions business 356 75.3 Business solutions business 82 17.4 Healthcare business 34 7.3」
The financial solutions business's revenue mix rose from 75.0% in the same period of the previous year to 75.3%, and the business solutions business rose from 11.9% to 17.4%, while the healthcare business declined from 13.1% to 7.3%. The contraction in the healthcare business further weakened portfolio diversification. - FY2020SoftenedAnnual report
「Financial solutions business 1,251 69.9 Financial solutions business 1,609 73.3 Business solutions business 246 13.8 Business solutions business 393 17.9 Healthcare business 293 16.3 Healthcare business 193 8.8」
The financial solutions business's share rose from 69.9% to 73.3%, while the healthcare business declined from 16.3% to 8.8%. The business solutions business expanded to 17.9%, but portfolio diversification weakened overall. - FY2020-Q3SoftenedAnnual report
「Financial solutions business 991 72.0 Business solutions business 227 16.6 Healthcare business 157 11.4」
The financial solutions business's share rose from 68.9% in the same period of the previous year to 72.0%, while the healthcare business declined from 16.7% to 11.4%. Portfolio diversification weakened during the quarter. - FY2020-Q2SoftenedAnnual report
「Financial solutions business 702 71.0 Business solutions business 189 19.1 Healthcare business 97 9.8」
The financial solutions business's revenue mix rose from 67.9% in the same period of the previous year to 71.0%, while the business solutions business rose from 15.8% to 19.1%. The healthcare business declined from 16.3% to 9.8%, weakening portfolio diversification during the quarter. - FY2020-Q1SoftenedAnnual report
「Financial solutions business 314 75.0 Business solutions business 50 11.9 Healthcare business 54 13.1」
The financial solutions business's revenue mix rose from 69.7% in the same period of the previous year to 75.0%, while the business solutions and healthcare businesses declined to 11.9% and 13.1%, respectively. Portfolio diversification weakened during the quarter. - FY2019AdvancedAnnual report
「The Group will secure stable orders in each of the financial solutions, business solutions and healthcare businesses and transition to a renewed growth phase.」
The annual report also sets out a policy of securing stable orders in each of the 3 businesses and transitioning to a renewed growth phase. Making Spider a core earnings driver, expanding adoption of GroupMAN@IT e² and adoption of IT Hanabiratake by major companies were cited as progress toward establishing an earnings base. - FY2019-Q3AdvancedAnnual report
「Financial solutions business 922 68.9 Business solutions business 191 14.4 Healthcare business 223 16.7」
The financial solutions business's share declined from 72.9% in the same period of the previous year to 68.9%, while the business solutions and healthcare businesses rose to 14.4% and 16.7%, respectively, advancing portfolio diversification. - FY2019-Q2AdvancedAnnual report
「Financial solutions business 616 67.9 Business solutions business 143 15.8 Healthcare business 147 16.3」
The financial solutions business's share declined from 73.8% in the same period of the previous year to 67.9%, while the business solutions and healthcare businesses rose to 15.8% and 16.3%, respectively, advancing portfolio diversification. - FY2019-Q1AdvancedAnnual report
「Financial solutions business 321 69.7 Business solutions business 58 12.6 Healthcare business 81 17.7」
While revenue declined in the financial solutions business, revenue increased in the business solutions and healthcare businesses, raising their respective revenue mix ratios from 10.9% and 15.1% in the same period of the previous year to 12.6% and 17.7%. - FY2018AdvancedAnnual report
「In the financial solutions business, the Group has previously focused system implementations on financial institutions, particularly securities companies. However, its next-generation infrastructure system Spider, built around new concepts such as blockchain, targets a wide range of operating companies and has also been adopted by major trading companies. Going forward, the Group will promote development and strengthen sales to make Spider a core earnings driver. In the business solutions segment, the number of companies adopting the GroupMAN@IT e² management control solution is also increasing. In the healthcare business, the Group's cultivated hana-maitake mushroom product IT Hanabiratake has been adopted by major companies, and the Group is working to establish an earnings base.」
The Group describes Spider's adoption by a major trading company, the increase in companies adopting GroupMAN@IT e² and the adoption of IT Hanabiratake by major companies as progress toward establishing an earnings base. - FY2018-Q3ReframedAnnual report
「To concentrate the Group's management resources on its core businesses, restore performance at an early stage and enhance corporate value.」
In addition to improving the balance of its existing business portfolio and returning to growth, the Group indicated that it would transfer its investment education business subsidiary and concentrate management resources on its core businesses. - FY2017AdvancedAnnual report
「In the business solutions segment, the number of companies adopting the GroupMAN@IT e² management control solution is increasing. In the healthcare business, the Group's cultivated hana-maitake mushroom product, IT Hanabiratake, has been adopted by major companies, indicating progress toward improving the business portfolio. The Group will secure stable orders in the business solutions and healthcare businesses as well as the financial solutions business, and transition to a renewed growth phase.」
The Group cites the increase in companies adopting GroupMAN@IT e² and the adoption of its hana-maitake mushroom product by major companies as progress in improving the portfolio, and has set out a transition to a renewed growth phase. - FY2016First statedAnnual report
「The Group's medium-term management strategy is to "achieve stable growth by improving the balance of its business portfolio." To reduce its dependence on the financial solutions business, which accounts for most of its revenue and is a core earnings driver, the Group launched its business solutions and healthcare businesses in the fiscal year ended September 2012.」
The Group has set out a medium-term strategy to reduce its dependence on the financial solutions business and achieve stable growth by improving the balance of its business portfolio.